Pimetine has been reported to be an antiatherogenic agent of particular interest since its activities are unrelated to blood cholesterol levels. Pimetine hydrochloride (IN 379) alters the production and utilization of acid mucopolysaeeharides and may block the formation of atherosclerotic plaque. The initial clinical evaluation of pimetine in neuropsychiatric disorders was performed in hospitalized patients with the diagnosis of "chronic brain syndrome". Behavioral effects of pimetine were increased alertness, interest and sociability with improvement in organization of thought processes. In patients suffering from chronic organic diseases, pimetine was reported to produce a feeling of "more energy", a general feeling of "well being" and mild insomnia was reported as a non-limiting side effect. Pimetine was found to be a less active stimulant than amphetamine.